Novel direct-acting anticoagulants for risk reduction in ACS

Paul P. Dobesh, Julie H. Oestreich

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Acute coronary syndrome (ACS) is a devastating adverse cardiovascular event with a massive burden on patient morbility and mortality, as well as the economy. Approximately 1.2 million people are hospitalized annually for ACS in the United States, with direct medical costs estimated at $150 billion in 2009. Rehospitalization is common, often as the result of recurrence of the initial event or complications of ACS or its therapy. Thrombosis is central to the pathogenesis of ACS. The current standard of care includes dual antiplatelet therapy, which reduces platelet activation and aggregation, integral steps for forming a thrombus. However, antiplatelet therapy does not prevent continued thrombin generation or the deposition of fibrin in the clot and residual risk of a recurrent event remains high. New oral anticoagulants offer a mechanism of action that is different from and complementary to that of antiplatelet agents. The ATLAS ACS-TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51) trial, using rivaroxaban, is the first trial of the new oral anticoagulants to show a benefit when added to antiplatelet therapy in reducing ACS events and mortality. While there was more major bleeding with the addition of rivaroxaban, fatal bleeding was not increased. These agents, if added to the current standard of care, might substantially reduce the high clinical and economic consequences of ACS.

Original languageEnglish (US)
Pages (from-to)358-366
Number of pages9
JournalJournal of Pharmacy Practice
Volume26
Issue number4
DOIs
StatePublished - Aug 2013

Fingerprint

Risk Reduction Behavior
Acute Coronary Syndrome
Anticoagulants
Standard of Care
Thrombosis
Therapeutics
Hemorrhage
Mortality
Platelet Aggregation Inhibitors
Platelet Activation
Fibrin
Platelet Aggregation
Thrombin
Myocardial Infarction
Economics
Costs and Cost Analysis
Recurrence

Keywords

  • acute coronary syndrome
  • anticoagulants
  • apixaban
  • dabigatran
  • rivaroxaban

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Novel direct-acting anticoagulants for risk reduction in ACS. / Dobesh, Paul P.; Oestreich, Julie H.

In: Journal of Pharmacy Practice, Vol. 26, No. 4, 08.2013, p. 358-366.

Research output: Contribution to journalArticle

@article{1a2845513cc046049ab50cfd502c798c,
title = "Novel direct-acting anticoagulants for risk reduction in ACS",
abstract = "Acute coronary syndrome (ACS) is a devastating adverse cardiovascular event with a massive burden on patient morbility and mortality, as well as the economy. Approximately 1.2 million people are hospitalized annually for ACS in the United States, with direct medical costs estimated at $150 billion in 2009. Rehospitalization is common, often as the result of recurrence of the initial event or complications of ACS or its therapy. Thrombosis is central to the pathogenesis of ACS. The current standard of care includes dual antiplatelet therapy, which reduces platelet activation and aggregation, integral steps for forming a thrombus. However, antiplatelet therapy does not prevent continued thrombin generation or the deposition of fibrin in the clot and residual risk of a recurrent event remains high. New oral anticoagulants offer a mechanism of action that is different from and complementary to that of antiplatelet agents. The ATLAS ACS-TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51) trial, using rivaroxaban, is the first trial of the new oral anticoagulants to show a benefit when added to antiplatelet therapy in reducing ACS events and mortality. While there was more major bleeding with the addition of rivaroxaban, fatal bleeding was not increased. These agents, if added to the current standard of care, might substantially reduce the high clinical and economic consequences of ACS.",
keywords = "acute coronary syndrome, anticoagulants, apixaban, dabigatran, rivaroxaban",
author = "Dobesh, {Paul P.} and Oestreich, {Julie H.}",
year = "2013",
month = "8",
doi = "10.1177/0897190012465954",
language = "English (US)",
volume = "26",
pages = "358--366",
journal = "Journal of Pharmacy Practice",
issn = "0897-1900",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Novel direct-acting anticoagulants for risk reduction in ACS

AU - Dobesh, Paul P.

AU - Oestreich, Julie H.

PY - 2013/8

Y1 - 2013/8

N2 - Acute coronary syndrome (ACS) is a devastating adverse cardiovascular event with a massive burden on patient morbility and mortality, as well as the economy. Approximately 1.2 million people are hospitalized annually for ACS in the United States, with direct medical costs estimated at $150 billion in 2009. Rehospitalization is common, often as the result of recurrence of the initial event or complications of ACS or its therapy. Thrombosis is central to the pathogenesis of ACS. The current standard of care includes dual antiplatelet therapy, which reduces platelet activation and aggregation, integral steps for forming a thrombus. However, antiplatelet therapy does not prevent continued thrombin generation or the deposition of fibrin in the clot and residual risk of a recurrent event remains high. New oral anticoagulants offer a mechanism of action that is different from and complementary to that of antiplatelet agents. The ATLAS ACS-TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51) trial, using rivaroxaban, is the first trial of the new oral anticoagulants to show a benefit when added to antiplatelet therapy in reducing ACS events and mortality. While there was more major bleeding with the addition of rivaroxaban, fatal bleeding was not increased. These agents, if added to the current standard of care, might substantially reduce the high clinical and economic consequences of ACS.

AB - Acute coronary syndrome (ACS) is a devastating adverse cardiovascular event with a massive burden on patient morbility and mortality, as well as the economy. Approximately 1.2 million people are hospitalized annually for ACS in the United States, with direct medical costs estimated at $150 billion in 2009. Rehospitalization is common, often as the result of recurrence of the initial event or complications of ACS or its therapy. Thrombosis is central to the pathogenesis of ACS. The current standard of care includes dual antiplatelet therapy, which reduces platelet activation and aggregation, integral steps for forming a thrombus. However, antiplatelet therapy does not prevent continued thrombin generation or the deposition of fibrin in the clot and residual risk of a recurrent event remains high. New oral anticoagulants offer a mechanism of action that is different from and complementary to that of antiplatelet agents. The ATLAS ACS-TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51) trial, using rivaroxaban, is the first trial of the new oral anticoagulants to show a benefit when added to antiplatelet therapy in reducing ACS events and mortality. While there was more major bleeding with the addition of rivaroxaban, fatal bleeding was not increased. These agents, if added to the current standard of care, might substantially reduce the high clinical and economic consequences of ACS.

KW - acute coronary syndrome

KW - anticoagulants

KW - apixaban

KW - dabigatran

KW - rivaroxaban

UR - http://www.scopus.com/inward/record.url?scp=84881134435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881134435&partnerID=8YFLogxK

U2 - 10.1177/0897190012465954

DO - 10.1177/0897190012465954

M3 - Article

C2 - 23172897

AN - SCOPUS:84881134435

VL - 26

SP - 358

EP - 366

JO - Journal of Pharmacy Practice

JF - Journal of Pharmacy Practice

SN - 0897-1900

IS - 4

ER -